UPenn receives ACGT grant for CAR T-cell clinical trial in prostate cancer

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

A scientific team is developing a CAR T-cell gene therapy for advanced metastatic prostate cancer at the Abramson Cancer Center of the University of Pennsylvania with a $500,000 grant from Alliance for Cancer Gene Therapy.

To access this subscriber-only content please log in or renew your subscription.

Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Login